• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Avacta Group PLC

News headline image
Avacta's pre|CISION Mechanism for Payload Delivery Shows Key Advantages Compared to an Antibody Drug Conjugate in Innovative AI-Driven Analysis
February 24, 2026
From Avacta Group PLC
Via GlobeNewswire
Tickers LSE
News headline image
Avacta appoints Francis Wilson as Chief Scientific Officer
February 09, 2026
From Avacta Group PLC
Via GlobeNewswire
Tickers LSE
News headline image
Avacta Announces Two Key Clinical Updates to its Faridoxorubicin Program
February 03, 2026
From AVACTA GROUP PLC
Via GlobeNewswire
Tickers LSE
News headline image
Avacta Announces U.S. Food and Drug Administration Clearance of the Investigational New Drug (IND) Application for the Second pre|CISION® Medicine, FAP-Exatecan (AVA6103)
January 21, 2026
From AVACTA GROUP PLC
Via GlobeNewswire
Tickers LSE
News headline image
Avacta Announces Year-end Trading Update
January 20, 2026
From AVACTA GROUP PLC
Via GlobeNewswire
Tickers LSE
News headline image
Faridoxorubicin (AVA6000) Phase 1b cohort demonstrates clinically meaningful tumor shrinkage in patients with salivary gland cancers
December 17, 2025
From AVACTA GROUP PLC
Via GlobeNewswire
Tickers LSE
News headline image
Avacta presents first preclinical data from dual payload pre|CISION® medicines at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets
October 25, 2025
From AVACTA GROUP PLC
Via GlobeNewswire
Tickers LSE
News headline image
Avacta Therapeutics Presents Compelling Phase 1a Data for Faridoxorubicin and the pre|CISION® Platform at the European Society of Medical Oncology Annual Congress
October 19, 2025
From AVACTA GROUP PLC
Via GlobeNewswire
Tickers LSE
News headline image
Avacta to Present First Dual Payload pre|CISION® Medicines Data at the 2025 EORTC-NCI-AACR International Conference on Molecular Targets Symposium
October 13, 2025
From AVACTA GROUP PLC
Via GlobeNewswire
Tickers LSE
News headline image
Avacta to Present New FAP Dox (AVA6000) Data at the European Society for Medical Oncology (ESMO) Congress
July 30, 2025
From AVACTA GROUP PLC
Via GlobeNewswire
Tickers LSE
News headline image
Avacta Appoints David Liebowitz, M.D., Ph.D. as Chief Medical Officer and Yulii Bogatyrenko as Advisor in Business Development
July 01, 2025
From AVACTA GROUP PLC
Via GlobeNewswire
Tickers INO LSE
News headline image
Avacta Therapeutics Announces Appointments of Industry Veterans to Board of Directors
May 28, 2025
From AVACTA GROUP PLC
Via GlobeNewswire
Tickers LSE
News headline image
Avacta Therapeutics Presents Data from Lead pre|CISION® Candidate FAP-Dox (AVA6000) at the 2025 AACR Annual Meeting
April 28, 2025
From AVACTA GROUP PLC
Via GlobeNewswire
Tickers LSE
News headline image
Avacta Therapeutics Presents Preclinical and Translational Data from pre|CISION® Platform Candidates at 2025 AACR Annual Meeting
April 28, 2025
From AVACTA GROUP PLC
Via GlobeNewswire
Tickers LSE
News headline image
Avacta Provides Business Update for the First Quarter of 2025 Outlining Progress Against Strategic Objectives
March 31, 2025
From AVACTA GROUP PLC
Via GlobeNewswire
Tickers LSE
News headline image
Avacta Therapeutics Announces Presentations at 2025 AACR Annual Meeting
March 26, 2025
From AVACTA GROUP PLC
Via GlobeNewswire
Tickers LSE
News headline image
Avacta Therapeutics to Present at the 2025 Leerink Global Healthcare Conference
March 10, 2025
From AVACTA GROUP PLC
Via GlobeNewswire
Tickers LSE
News headline image
Avacta Announces Promising Early Efficacy and Safety Data for AVA6000 in the Phase 1a Dose Escalation and Ongoing Enrollment in the Phase 1b Expansion Cohorts
March 07, 2025
From AVACTA GROUP PLC
Via GlobeNewswire
Tickers LSE
News headline image
Avacta Announces Agreement to Sell Launch Diagnostics and a Corporate Update
March 07, 2025
From AVACTA GROUP PLC
Via GlobeNewswire
News headline image
Avacta Announces Positive New Data from the AVA6000 Phase 1 trial Demonstrating Clinically Meaningful Tumor Shrinkage in Patients with Salivary Gland Cancers
January 16, 2025
From AVACTA GROUP PLC
Via GlobeNewswire
News headline image
Avacta Appoints Brian Hahn as Chief Financial Officer
January 13, 2025
From AVACTA GROUP PLC
Via GlobeNewswire
News headline image
Avacta Announces Successful Completion of Fifth Dose Escalation in AVA6000 Phase 1 Clinical Study
June 21, 2023
From Avacta Group plc
Via Business Wire
News headline image
First Patient Dosed in the US in Avacta’s AVA6000 Phase 1 Clinical Study
April 27, 2023
From Avacta Group plc
Via Business Wire
News headline image
Avacta Opens First Two US Clinical Investigator Sites for AVA6000 Phase 1 Clinical Study
April 06, 2023
From Avacta Group plc
Via Business Wire
News headline image
Avacta Announces First Patient Dosed in Fifth Cohort of AVA6000 Phase Ia Dose Escalation Study
April 05, 2023
From Avacta Group plc
Via Business Wire
News headline image
Avacta Appoints Karen Harrison as Chief Operating Officer for Therapeutics Division
March 28, 2023
From Avacta Group plc
Via Business Wire
News headline image
Avacta to Present Pre-Clinical Data on AVA3996 at the American Association for Cancer Research Annual Meeting
March 27, 2023
From Avacta Group plc
Via Business Wire
News headline image
Avacta Announces Successful Completion of Fourth Dose Escalation in AVA6000 Phase 1 Clinical Study
January 17, 2023
From Avacta Group plc
Via Business Wire
News headline image
Avacta Announces AVA6000 Receives Orphan Drug Designation From the US Food and Drug Administration
September 05, 2022
From Avacta Group plc
Via Business Wire
News headline image
Avacta Announces Phase I Clinical Study of AVA6000 to Advance to the Fourth Cohort
September 01, 2022
From Avacta Group plc
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap